Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 11-20 of 27 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Dasatinib And Quercetin With CAR T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

    Rochester, MN

  2. A Study Of Prehabilitation In Patients With Multiple Myeloma Receiving CAR-T Therapy

    Rochester, MN

  3. A Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, In Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

    Jacksonville, FL

  4. Long-Term Follow-up Protocol For Participants Treated With Gene-Modified T Cells

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. A Study To Evaluate The Safety And Effectiveness Of Idecabtagene Vicleucel To Treat Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  6. Epcoritamab Compared To Observation For Treating B-cell Lymphoma Patients Not In Complete Remission After CD19-directed CAR-T Therapy

    Jacksonville, FL, Rochester, MN

  7. Axicabtagene Ciloleucel Versus Standard Of Care Therapy As First-Line Therapy In High-Risk Large B-Cell Lymphoma

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, La Crosse, WI, Mankato, MN, Rochester, MN

  8. A Study To Evaluate The Safety And Efficacy Of A2B395, An Allogeneic Logic-gated CAR T, In Participants With Solid Tumors That Express EGFR And Have Lost HLA-A*02 Expression

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. PRGN-3006 Adoptive Cellular Therapy For CD33-Positive Relapsed Or Refractory AML, MRD Positive AML Or Higher Risk MDS

    Rochester, MN

  10. Safety And Efficacy Of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cells In Subjects With Relapsed Or Refractory BAFFR-expressing B-cell Hematologic Malignancies

    Jacksonville, FL

.

Mayo Clinic Footer